{"url_path":"/sec/uncy/8-k/2026-06-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-070316-index.html","accession_number":"0001213900-26-070316","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-070316-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":310,"has_tables":true,"body_markdown":"false\n0001766140\n\n0001766140\n\n2026-06-19\n2026-06-19\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND\nEXCHANGE COMMISSION**\n\n**Washington, DC\n20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13\nor 15(d) of the Securities Exchange Act of 1934**\n\n** **\n\nDate of Report (Date\nof earliest event reported): **June 19, 2026**\n\n \n\n**Unicycive Therapeutics, Inc.**\n\n(Exact name of registrant\nas specified in its charter)\n\n \n\n**Delaware**\n \n**001-40582**\n \n**81-3638692**\n\n(State\nor other jurisdiction of\n \n(Commission File Number)\n \nIRS\nEmployer\n\nincorporation or organization)\n \n \n \nIdentification\nNo.)\n\n \n\n**1975 W. El Camino Real, Suite 204**\n\n**Mountain View, CA 94040**\n\n(Address of principal\nexecutive offices)\n\n \n\nRegistrant’s\ntelephone number, including area code: **(650) 351-4495**\n\n \n\n \n\n(Former name or\nformer address, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title\nof each class:**\n \n**Trading\nSymbol(s)**\n \n**Name of each exchange\non which registered:**\n\nCommon Stock\n \nUNCY\n \nNasdaq Capital Market\n\n \n\nCheck the appropriate box below if the\nForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten\ncommunication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☒\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). \n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth\ncompany, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}